- Page 1:
AUTOLOGOUS BLOOD AND MARROW TRANSPL
- Page 5 and 6:
AUTOLOGOUS BLOOD AND MARROW TRANSPL
- Page 7:
ACKNOWLEDGMENTS We wish to thank Wi
- Page 11:
THE VAN BEKKUM STEM CELL AWARD Prof
- Page 14 and 15:
xii Table of Contents CHAPTER 2: AL
- Page 16 and 17:
xiv Table of Contents Late Non-Rela
- Page 18 and 19:
xvi Table of Contents Pretreatment
- Page 20 and 21:
xviii Table of Contents CHAPTER 7:
- Page 22 and 23:
XX Table of Contents Long-Term Obse
- Page 24 and 25:
xxii Table of Contents CHAPTER 13:
- Page 27 and 28:
0-9 LIST OF ABBREVIATIONS 2CDA 2-ch
- Page 29 and 30:
List of Abbreviations xxvii EFS eve
- Page 31 and 32:
List of Abbreviations MOPP mechlore
- Page 33:
VOD veno-occlusive disease VPC viru
- Page 37 and 38:
4HC-Purged Autologous Stem Cell Tra
- Page 39 and 40:
1.0-1 + 0.2 Miller et al. 5 Event F
- Page 41 and 42:
Miller et al. Adjusted probability
- Page 43 and 44:
Who Benefits From Autograft in AML
- Page 45 and 46:
Burnett 11 which to set the transpl
- Page 47 and 48:
Table 1. Outcome after relapse in M
- Page 49 and 50:
Immunotherapy in AML: No Positive E
- Page 51 and 52:
Simonsson et al. inhibit IL-2 induc
- Page 53 and 54:
Autologous Bone Marrow Transplantat
- Page 55 and 56:
Ball et al. 21 CD15) and AML-2-23 (
- Page 57 and 58:
Ball et al. 23 The ex vivo treatmen
- Page 59 and 60:
Ball et al. 25 Table 2. Factors inv
- Page 61 and 62:
Ball et al. Overall Survival for Pa
- Page 63 and 64:
Ball et al. Overall Survival for Pa
- Page 65 and 66:
Ball et al. 31 Overall Survival for
- Page 67 and 68:
Ball et al. Table 4. Actuarial over
- Page 69 and 70:
Ball et al. myeloid leukemia. The G
- Page 71 and 72:
Ball et al. 1993. 38. Mehta J, Powl
- Page 73 and 74:
Can Autologous Stem Cell Transplant
- Page 75 and 76:
De Witte et al. 41 novo AML. Auer r
- Page 77 and 78:
De Witte et al. hematopoietic engra
- Page 79 and 80:
De Witte et al. 23. Fenaux P, Laï
- Page 81 and 82:
Stein et al. and fever. No patient
- Page 83 and 84:
Stein et al. after doses 1, 3, and
- Page 85 and 86:
Stein et al. early after the transp
- Page 87:
autologous stem-cell rescue. / Clin
- Page 91 and 92:
Bone Marrow Transplantation for Acu
- Page 93 and 94:
Table 2. Autologous BMT in ALL in f
- Page 95 and 96:
Rowe 61 or adult patients with acut
- Page 97 and 98:
Hoelzer and Gôkbuget minitransplan
- Page 99 and 100:
Hoelzer and Gdkbuget 65 blood, earl
- Page 101 and 102:
Table 3. Risk factors for the defin
- Page 103 and 104:
Hoelzer and Gôkbuget treatment opt
- Page 105 and 106:
Hoeker and Gökbuget tical sibling
- Page 107 and 108:
Sierra et al. INTRODUCTION Two-thir
- Page 109 and 110:
Sierra et al. Table 2. Adverse char
- Page 111 and 112:
1,0 0,0 J Sierra et al. 0 20 40 60
- Page 113 and 114:
Sierra et al. Months Figure 4 < 30,
- Page 115 and 116:
Sierra et al. No adverse factors (n
- Page 117 and 118:
1994. Sierra et al. 83 10. Canals C
- Page 119 and 120:
Martin, Atta, and Hoelzer 85 adult
- Page 121 and 122:
Martin, Atta, and Hoelzer 87 Single
- Page 123 and 124:
100. Martin, Atta, and Hoelzer 89 P
- Page 125 and 126:
Martin, Atta, and Hoelzer 91 chromo
- Page 127 and 128:
Autologous vs. Unrelated Allogeneic
- Page 129 and 130:
Boyer and Yeager 95 outcomes after
- Page 131 and 132:
Boyer and Y eager 97 Table 2. Hypot
- Page 133 and 134:
Boyer and Y eager SUMMARY Most of t
- Page 135:
CHAPTER 3 CML
- Page 138 and 139:
Autograft Followed by Allograft Wit
- Page 140 and 141:
106 Chapter 3: CML (one low-grade a
- Page 142 and 143:
108 Chapter 3: CML DISCUSSION Myelo
- Page 144 and 145:
110 Chapter 3: CML Philadelphia-neg
- Page 146 and 147:
The Case for Manipulation of CML Au
- Page 148 and 149:
Toward a Cure by Drug Treatment? Th
- Page 150 and 151:
116 Chapter 3 :CML Table 1. Prolong
- Page 152 and 153:
118 Chapter 3: CML Table 3. German
- Page 154 and 155:
120 Chapter 3: CML Table 5. Normal
- Page 156 and 157:
122 Chapter 3: CML Table 8. Surviva
- Page 158 and 159:
124 Chapter 3: CML 88:3118-3122, 19
- Page 160 and 161:
126 Chapter 3: CML RK, Klingemann H
- Page 162 and 163:
The Tyrphostin AG957 Inhibits the I
- Page 164 and 165:
130 Chapter 3: CML mobilization. Al
- Page 166 and 167:
132 Chapter 3: CML A B 100 n 0 1 5
- Page 168 and 169:
134 Chapter 3: CML The in vitro sel
- Page 170 and 171:
136 Chapter 3: CML detecting leukem
- Page 173 and 174:
Progressive Hodglcin's Lymphoma Fol
- Page 175 and 176:
Reece et al. survival is observed i
- Page 177 and 178:
0.2 -I 0.0 0 Reece et al. 143 ii i
- Page 179 and 180:
Reece et al. Table 3. Causes of non
- Page 181 and 182:
Reece et al. carmustine, etoposide
- Page 183 and 184:
CD34 + Selection of Hematopoietic B
- Page 185 and 186:
Lazarus et al. 151 significantly de
- Page 187 and 188:
Lazarus et al. 153 (Sigma, St Louis
- Page 189 and 190:
Lazarus et al. 155 Table 2. Effect
- Page 191 and 192:
Lazarus et al. 157 difference. Furt
- Page 193 and 194:
Lazarus et al. 159 cells after myel
- Page 195 and 196:
The European CUP/UP Trial: A Prelim
- Page 197 and 198:
Table 1. Patient characteristics at
- Page 199 and 200:
Schouten et al. licular non-Hodgkin
- Page 201 and 202:
Sweetenham et al. vs. autologous pe
- Page 203 and 204:
Table 1. Patient characteristics, g
- Page 205 and 206:
Table 2. Patient characteristics, g
- Page 207 and 208:
Table 3. Sites of relapse, group A
- Page 209 and 210:
Table 4. Patterns of relapse, group
- Page 211 and 212:
A 100 80 %OS 60 40 20 B 100 %OS | S
- Page 213 and 214:
Sweetenham et al. new sites, and fi
- Page 215 and 216:
Sweetenham et al. Treatment options
- Page 217 and 218:
Molecular Remission: A Worthwhile A
- Page 219 and 220:
Early or Late Autotransplant in Hig
- Page 221 and 222:
Schenkein et al. 187 PATIENTS AND M
- Page 223 and 224:
Schenkein et al. 189 Toxicity Toxic
- Page 225 and 226:
Schenkein et al. 191 16. Glick JH,
- Page 227 and 228:
Santini et al. 193 to evaluate the
- Page 229 and 230:
Table 1. Continued Santini et al. 1
- Page 231 and 232:
Santini et al. 197 cytosine arabino
- Page 233 and 234:
1 0 0 1 90- 80- 70- (0 u. 60' o so-
- Page 235 and 236:
Hodgkin's lymphoma. N EnglJ Med 333
- Page 237:
CHAPTER 5 MYELOMA
- Page 240 and 241:
206 Chapter 5: Myeloma independent
- Page 242 and 243:
208 Chapter 5: Myeloma disease (MRD
- Page 244 and 245:
210 Chapter 5: Myeloma Scandinavia,
- Page 246 and 247:
212 Chapter 5: Myeloma (0 n o B co
- Page 248 and 249:
214 Chapter 5: Myeloma B cq d ? o c
- Page 250 and 251:
216 Chapter 5: Myeloma patients wit
- Page 252 and 253:
218 Chapter 5: Myeloma PBSC transpl
- Page 254 and 255:
220 Chapter 5: Myeloma 25. Seiden M
- Page 256 and 257:
Autologous Transplantation in Multi
- Page 258 and 259:
224 Chapter 5: Myeloma 0 52 44 U §
- Page 260 and 261:
226 Chapter 5: Myeloma BM ^ (CD34±
- Page 262 and 263:
228 Chapter 5: Myeloma IFM 94 : OS
- Page 264 and 265:
230 Chapter 5: Myeloma two groups a
- Page 266 and 267:
232 Chapter 5: Myeloma increase bot
- Page 268 and 269:
234 Chapter 5: Myeloma REFERENCES 1
- Page 270 and 271:
236 Chapter 5: Myeloma Intensified
- Page 272 and 273:
238 Chapter 5: Myeloma of CD34 + ce
- Page 274 and 275:
Chapter 5: Myeloma Table 2. Descrip
- Page 276 and 277:
242 Chapter 5: Myeloma o 8H 0 2 4 6
- Page 278 and 279:
244 Chapter 5: Myeloma ated with sh
- Page 281 and 282:
The Presence of Micrometastases in
- Page 283 and 284:
Kvalheim et al. 249 Table 1. Immuno
- Page 285 and 286:
Kvalheim et al. 251 Figure 1. Sixty
- Page 287 and 288:
Kvalheim et al. 253 DISCUSSION In t
- Page 289 and 290:
Kvalheim et al. 255 Bastert G: Micr
- Page 291 and 292:
Hood et al. 257 In an effort to inc
- Page 293 and 294:
#CD34 + cells in blood = Hood et al
- Page 295 and 296:
Hood et al. 261 Table 3. Frequency
- Page 297 and 298:
Hood et al. 263 REFERENCES 1. Rill
- Page 299 and 300:
The Clinical Significance of Breast
- Page 301 and 302:
Moss et al. tests, and bilateral po
- Page 303 and 304:
Moss et al. 269 0 15 70 143 200 400
- Page 305 and 306:
Moss et al. 271 0 3 6 12 18 24 30 3
- Page 307 and 308:
Moss et al. 273 8. Passos-Coelho J,
- Page 309 and 310:
Autotransplantation for Men With Br
- Page 311 and 312:
McCarthy et al. 277 radiation, two
- Page 313 and 314:
High Dose Sequential Chemotherapy W
- Page 315 and 316:
Viens et al. 281 3 g/m 2 and doxoru
- Page 317 and 318:
Table 1. Tumor characteristics Exte
- Page 319 and 320:
Table 4. Response Viens et al. 285
- Page 321 and 322:
Viens et al. 287 Table 5. Pathologi
- Page 323 and 324:
Viens et al. 289 apy for inoperable
- Page 325 and 326:
Gliick et al. 291 INTRODUCTION The
- Page 327 and 328:
Gluck et al. 293 RESULTS Patient de
- Page 329 and 330:
Glück et al. 295 Table 3. Response
- Page 331 and 332:
Gluck et al. 297 Overall Survival O
- Page 333 and 334:
Gluck et al. 299 Sudbury patients w
- Page 335 and 336:
Gluck et al. 301 anthracycline or t
- Page 337 and 338:
Repetitive High-Dose Therapy With P
- Page 339 and 340:
Prince et al. paramagnetic separati
- Page 341 and 342:
Prince et al. Table 1. High-dose re
- Page 343 and 344:
Table 2. Patient characteristics (n
- Page 345 and 346:
Table 4. Hematopoietic recovery fol
- Page 347 and 348:
1.0- M C .S 0.8- a c *fe o o> 0.6-
- Page 349 and 350:
M 1.0 I 0.8H s? VI o.6H S 0.2 0.0 P
- Page 351 and 352:
a Prince et al. days to platelets >
- Page 353 and 354:
Table 5. Results of Isolex 300i CD3
- Page 355 and 356:
Prince et al. 321 Figure 5, continu
- Page 357 and 358:
Prince et al. 323 months after tran
- Page 359 and 360:
Prince et al. 325 excessive to be u
- Page 361 and 362:
Prince et al. 327 eight patients ha
- Page 363 and 364:
Prince et al. 329 marrow transplant
- Page 365 and 366:
Prince et al. intensive chemotherap
- Page 367 and 368:
-Q CO .Q O 1.0 0.9 0.8 0.7 0.6 0.5
- Page 369 and 370:
.Q CD .Q O 1.0 0.9 0.8 0.7 0.6 0.5
- Page 371 and 372:
oba Q. 1.0 0.9 Dicke et al. Stage I
- Page 373 and 374:
Vahdat with peripheral blood progen
- Page 375 and 376:
Evaluation of Prognostic Factors fo
- Page 377 and 378:
Fields et al. 343 PATIENTS AND METH
- Page 379 and 380:
Table 1. Chemotherapy regimens. Fie
- Page 381 and 382:
Fields et al. Stage II; 4-9 Pos LN
- Page 383 and 384:
U U Fields et al.
- Page 385 and 386:
Fields et al. 351 between 1 and 2 y
- Page 387 and 388:
European Trends and the EBMT Databa
- Page 389 and 390:
25% % 22% / 17% \ Rosti et al. 355
- Page 391 and 392:
Rosti et al. 357 The new Italian St
- Page 393 and 394:
- Page 395 and 396:
Rosti et al. 6. Haas R, Schmid H, H
- Page 397 and 398:
Bewick et al. 363 INTRODUCTION The
- Page 399 and 400:
Bewick et al. 365 Blood samples obt
- Page 401 and 402:
Bewick et al. 367 HDCT with ABSC su
- Page 403 and 404:
Bewick et al. Progression Free Surv
- Page 405 and 406:
Bewick et al. pression in MBC, i.e.
- Page 407 and 408:
Bewick et al. 14. Kandl HL, Seymour
- Page 409:
CHAPTER 7 OTHER SOLID TUMORS
- Page 412 and 413:
378 Chapter 7: Solid Tumors INTRODU
- Page 414 and 415:
380 Chapter 7: Solid Tumors Prepara
- Page 416 and 417:
382 Chapter 7: Solid Tumors Surviva
- Page 418 and 419:
384 Chapter 7: Solid Tumors months
- Page 420 and 421:
386 Chapter 7: Solid Tumors have be
- Page 422 and 423:
High-Dose Chemotherapy in the Manag
- Page 424 and 425:
390 Chapter 7: Solid Tumors followe
- Page 426 and 427:
392 Chapter 7: Solid Tumors Table 1
- Page 428 and 429:
394 Chapter 7: Solid Tumors (mucosi
- Page 430 and 431:
Three-Fold Intensification by Seque
- Page 432 and 433:
398 Chapter 7: Solid Tumors Table 2
- Page 434 and 435:
400 Chapter 7: Solid Tumors Table 4
- Page 436 and 437:
High-Dose Therapy for Small Cell Lu
- Page 438 and 439:
404 Chapter 7: Solid Tumors chemoth
- Page 440 and 441:
406 Chapter 7: Solid Tumors SCLC ha
- Page 442 and 443:
408 Chapter 7: Solid Tumors relapse
- Page 444 and 445:
410 Chapter 7: Solid Tumors 69:585-
- Page 446 and 447:
412 Chapter 7: Solid Tumors ogous b
- Page 448 and 449:
414 Chapter 7: Solid Tumors 64. Bru
- Page 450 and 451:
416 Chapter 7: Solid Tumors Prignot
- Page 452 and 453:
418 Chapter 7: Solid Tumors CO > CO
- Page 454 and 455:
420 Chapter 7: Solid Tumors TANDEM
- Page 456 and 457:
Multiple Courses of Cyclophosphamid
- Page 458 and 459:
424 Chapter 7: Solid Tumors and the
- Page 460 and 461:
426 Chapter 7: Solid Tumors Thiotep
- Page 462 and 463:
428 Chapter 7: Solid Tumors Table 2
- Page 464 and 465:
430 Chapter 7: Solid Tumors E 100 0
- Page 466 and 467:
432 Chapter 7: Solid Tumors course
- Page 468 and 469:
434 Chapter 7: Solid Tumors boplati
- Page 470 and 471:
436 Chapter 7: Solid Tumors INTRODU
- Page 472 and 473:
438 - Chapter 7: Solid Tumors Table
- Page 474 and 475:
440 Chapter 7: Solid Tumors seeded
- Page 476 and 477:
442 Chapter 7: Solid Tumors DISCUSS
- Page 478 and 479:
444 Chapter 7: Solid Tumors 10. Di
- Page 480 and 481:
446 Chapter 7: Solid Tumors plasma
- Page 483 and 484:
Autologous Stem Cell Transplantatio
- Page 485 and 486:
Keystone 451 hypertension, anemia,
- Page 487 and 488:
Fassas et al. 453 INTRODUCTION Mult
- Page 489 and 490:
Fassas et al. Table 2. Stem cell mo
- Page 491 and 492:
Table 3. Toxicity after stem cell i
- Page 493 and 494: Fassas et al. Table 5. Trial 1: cha
- Page 495 and 496: Fassas et al. MS PROGRESSION FREE S
- Page 497 and 498: Fassas et al. ic or autologous bone
- Page 499 and 500: 1 2 1 6 EAE. Burt et al. 465 Becaus
- Page 501 and 502: Burt et al. Since cyclophosphamide
- Page 503 and 504: Burt et al. 469 toxicity study, we
- Page 505 and 506: Burt et dl. All 23. Mor F, Cohen IR
- Page 507 and 508: Hasler, Gratwohl, and Tyndall an ev
- Page 509 and 510: Hasler, Gratwohl, and Tyndall 475 B
- Page 511 and 512: Kuis, Wulffraat, and Sanders 477 st
- Page 513 and 514: Kuis, Wulffraat, and Sanders neousl
- Page 515: CHAPTER 9 LONG-TERM EFFECTS
- Page 518 and 519: 484 Chapter 9: Long-Term Effects po
- Page 520 and 521: 486 Chapter 9: Long-Term Effects Ta
- Page 522 and 523: 488 Chapter 9: Long-Term Effects ml
- Page 524 and 525: 490 Chapter 9: Long-Term Effects 4.
- Page 526 and 527: 492 Chapter 9: Long-Term Effects us
- Page 528 and 529: 494 Chapter 9: Long-Term Effects AB
- Page 530 and 531: 496 Chapter 9: Long-Term Effects Ta
- Page 532 and 533: 498 Chapter 9: Long-Term Effects En
- Page 534 and 535: 500 Chapter 9: Long-Term Effects Rl
- Page 536 and 537: 502 Chapter 9: Long-Term Effects RE
- Page 538 and 539: 504 Chapter 9: Long-Term Effects A,
- Page 540 and 541: Long-Term Follow-Up of Autologous T
- Page 542 and 543: 508 Chapter 9: Long-Term Effects Ta
- Page 547 and 548: Gene Marking to Assess Tumor Contam
- Page 549 and 550: Heslop et al. 515 clonogenic assays
- Page 551 and 552: Heslop et al. 517 Disease Free Surv
- Page 553 and 554: Heslop et al. 519 providing the cli
- Page 555 and 556: Enrichment of Tumor Cells From Auto
- Page 557 and 558: Ross et al. post-TEC fraction was c
- Page 559 and 560: Ross et al. 525 Table 2. Results of
- Page 561 and 562: Ross et al. that the capture antibo
- Page 563 and 564: Combining Positive/Negative Selecti
- Page 565 and 566: Mapara et al. 531 products of patie
- Page 567 and 568: Mapara et al. 533 Hematopoietic col
- Page 569 and 570: Mapara et al. 535 A i m : P u r g i
- Page 571 and 572: Mapara et al. 537 A |_ «••«
- Page 573 and 574: Mapara et al. 539 11. Shpall EJ, Le
- Page 575 and 576: Tumor Purging Technologies: More Qu
- Page 577 and 578: Gee 543 argued that these two patie
- Page 579 and 580: Gee 545 immunomagnetic particles to
- Page 581 and 582: Gee 547 POSITIVE OR NEGATIVE? Given
- Page 583 and 584: Gee 549 autologous transplants of c
- Page 585 and 586: Behavior of Hematopoietic Stem Cell
- Page 587 and 588: Henschler et al. 553 MATERIALS AND
- Page 589 and 590: Table 1. Engraftment of human CD34
- Page 591 and 592: Henschler et al. 557 an increase of
- Page 593 and 594: Henschler et dl. 559 plantation for
- Page 595 and 596:
CD34 Selection and Autografting in
- Page 597 and 598:
Table 1. Patient characteristics, n
- Page 599 and 600:
Voso et al. 565 The side scatter (S
- Page 601 and 602:
Table 3. Immunophenotype of CD34 +
- Page 603 and 604:
Voso et al. 569 neuroblastoma and a
- Page 605 and 606:
Voso et al. 571 transplantation for
- Page 607 and 608:
Neutrophils Days 100 Days to >500
- Page 609 and 610:
Dicke et al. 575 CD34 Labeling Samp
- Page 611 and 612:
Dicke et al. 577 Table 3. Platelet
- Page 613 and 614:
Dicke et al. 579 3. Ager S, Scott M
- Page 615 and 616:
Janssen et al. 581 PBSC products. H
- Page 617 and 618:
Janssen et al. Table 1. Characteris
- Page 619 and 620:
5X10 5 Janssen et ai. 585 In brief,
- Page 621 and 622:
Janssen et al. CD34+ CELLS INFUSED/
- Page 623 and 624:
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2
- Page 625 and 626:
Janssen et al. RELAPSE FREE SURVIVA
- Page 627 and 628:
CD34 + Janssen et al. cells and CFU
- Page 629 and 630:
Janssen et al. 595 8. Dercksen MW,
- Page 631 and 632:
Janssen et al. 597 32. Sosman JA, S
- Page 633:
CHAPTER 11 MINITRANSPLANTS
- Page 636 and 637:
602 Chapter 11: Minitransplants to
- Page 638 and 639:
604 Chapter 11: Minitransplants Tab
- Page 640 and 641:
606 Chapter 11: Minitransplants Tab
- Page 642 and 643:
608 Chapter 11: Minitransplants tra
- Page 644 and 645:
610 Chapter 11: Minitransplants 14.
- Page 646 and 647:
Allogeneic Progenitor Cell Transpla
- Page 648 and 649:
614 Chapter 11: Minitransplants 100
- Page 650 and 651:
616 Chapter 11: Minitransplants Tab
- Page 652 and 653:
618 Chapter 11: Minitransplants all
- Page 655 and 656:
Transduction of Primitive Hematopoi
- Page 657 and 658:
Jordan et al. shown that such a hyb
- Page 659 and 660:
Table 1. Initial findings with seve
- Page 661 and 662:
Jordan et al. In preclinical studie
- Page 663 and 664:
Molecular Intervention in Myeloma A
- Page 665:
CHAPTER 13 IMMUNOTHERAPY
- Page 668 and 669:
Immune-toxins Containing Pokeweed A
- Page 670 and 671:
636 Chapter 13: Immunotherapy tumor
- Page 672 and 673:
638 Chapter 13: Immunotherapy unide
- Page 674 and 675:
640 Chapter 13: Immunotherapy lymph
- Page 676 and 677:
642 Chapter 13: Immunotherapy accom
- Page 678 and 679:
644 Chapter 13: Immunotherapy Figur
- Page 680 and 681:
646 Chapter 13: Immunotherapy CD80P
- Page 682 and 683:
648 Chapter 13: Immunotherapy are o
- Page 684 and 685:
650 Chapter 13: Immunotherapy 23. F
- Page 686 and 687:
652 Chapter 13: Immunotherapy 57. T
- Page 688 and 689:
Adjuvant Immunotherapy in Conjuncti
- Page 690 and 691:
656 Chapter 13: Immunotherapy mg/m
- Page 692 and 693:
658 Chapter 13: Immunotherapy NHL a
- Page 694 and 695:
660 Chapter 13: Immunotherapy tion
- Page 696 and 697:
662 Chapter 13: Immunotherapy Table
- Page 698 and 699:
664 Chapter 13: Immunotherapy leuke
- Page 701 and 702:
The Brambell Receptor (FcRB) and th
- Page 703 and 704:
5h P 11- V Junghans 669 o I 1 1 1 1
- Page 705 and 706:
Junghans 10 20 30 40 IgG Concentrat
- Page 707 and 708:
1001- 90 80 E 70 § 60 K g 50 u z 8
- Page 709 and 710:
Junghans 675 Time, days Figure 8. B
- Page 711 and 712:
Junghans 677 The site on Fc for int
- Page 713 and 714:
Junghans 679 1969. 20. Junghans RP,
- Page 715 and 716:
Approaches to the Radiation Dosimet
- Page 717 and 718:
Fisher 683 bution to marrow dose is
- Page 719 and 720:
Fisher 685 organ k per unit cumulat
- Page 721 and 722:
Fisher 687 acetabulum. The curve is
- Page 723 and 724:
Fisher 689 Table 2. Correlations be
- Page 725 and 726:
Fisher 8. Sgouros G: Bone marrow do
- Page 727:
Radioimmunotherapy for Malignant Ly
- Page 731 and 732:
Induction of Graft-vs.-Malignancy a
- Page 733 and 734:
Champlin, Khouri, and Giralt 699 is
- Page 735 and 736:
Champlin, Khouri, and Girat 701 and
- Page 737 and 738:
Champlin, Khouri, and Giralt 703 ti
- Page 739 and 740:
Champlin, Khouri, and Giralt 705 A
- Page 741 and 742:
Champlin, Khouri, and Giralt 707 E,
- Page 743 and 744:
Whimbey 709 INTRODUCTION Infectious
- Page 745 and 746:
Whimbey 711 CRVs are a common cause
- Page 747 and 748:
Whimbey 713 antibody titers to RSV
- Page 749 and 750:
Whimbey 715 toxic, less costly, and
- Page 751 and 752:
Asymmetric Division as Measurable P
- Page 753:
Neuropoiesis Peter Quesenberry, Car
- Page 757 and 758:
Summary: Leukemia John Barrett Bone
- Page 759 and 760:
Barrett New directions A role for i
- Page 761 and 762:
Autologous Blood and Marrow Transpl
- Page 763 and 764:
across page) Elfenbein 729 Examples
- Page 765 and 766:
Elfenbein 731 Examples Contributors
- Page 767 and 768:
Table 3. Types of clinical trials i
- Page 769 and 770:
Strategies in Autologous Bone Marro
- Page 771 and 772:
Summary: Lymphoma Armand Keating On
- Page 773 and 774:
Rafat Abonour Indiana Univ. Cancer
- Page 775 and 776:
H-Joachim Deeg Fred Hutchinson Canc
- Page 777 and 778:
Richard P. Junghans Division of Hem
- Page 779 and 780:
Peter J. Quesenberry Univ. of Massa
- Page 781 and 782:
Linda T. Vahdat Columbia Presbyteri
- Page 783 and 784:
DiStefano, Alfred 332 Dodero, Anna
- Page 785 and 786:
Author Index 751 Ohno-Jones, S. 113
- Page 787 and 788:
KEY WORD INDEX 4-HC 1 Brambell rece
- Page 789:
Refractory anemia with excess blast